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INTRODUCTION 
 
Longevity and relative longevity with preserved 
physiologic function or low levels of disease are types 
of “exceptional survival,” a term promoted by the 
National Institute on Aging Advisory Panel on 
Exceptional Longevity [1] to encompass multiple 
outcomes  for  the  study  of  healthy  aging.   The   term  
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“exceptional survival” refers to “important survival 
outcomes such as survival without disease or disability, 
as well as to longevity per se.” Compression of 
disability and/or morbidity towards the end of very long 
lives has been noted to be associated with exceptional 
longevity which in turn has been found to be strongly 
familial [2-4]. 
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Abstract: Individuals from families recruited for the Long Life Family Study (LLFS) (n= 4559)  were examined and compared
to  individuals  from  other  cohorts  to  determine  whether  the  recruitment  targeting  longevity  resulted  in  a  cohort  of
individuals with better health and function.  Other cohorts with similar data included the Cardiovascular Health Study, the
Framingham Heart Study, and the New England Centenarian Study.  Diabetes, chronic pulmonary disease and peripheral
artery disease tended to be less common in LLFS probands and offspring compared to similar aged persons in the other
cohorts.  Pulse pressure and triglycerides were lower, high density lipids were higher, and a perceptual speed task and gait
speed were better in LLFS.  Age‐specific comparisons showed differences that would be consistent with a higher peak, later
onset  of  decline  or  slower  rate  of  change  across  age  in  LLFS  participants.  These  findings  suggest  several  priority
phenotypes for inclusion in future genetic analysis to identify loci contributing to exceptional survival. 
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effort to enroll families clustered for exceptional 
survival in order to identify environmental and genetic 
factors that promote long healthy lives in these family 
members. The recruitment of families into the LLFS 
focused on selecting families with multiple 
exceptionally old living individuals. The offspring 
generation has not yet had the opportunity to manifest 
longevity; this will take years of follow-up. However, 
their exceptionality might manifest as lower prevalence 
of diseases that are the major contributors to mortality 
in older adults as has been demonstrated in the offspring 
of centenarians and the Framingham Heart Study (FHS) 
[5,6].  Because of more robust health or absence of 
disabling disease, they may also show unusually high 
physical and cognitive function for their age. The initial 
examination of LLFS participants was designed to 
capture several of these exceptional survival 
phenotypes.  
 
This paper compares the prevalence of disease as well 
as physical and cognitive functioning in LLFS probands 
and offspring to two community based cohorts that were 
not selected for longevity. These comparison cohorts 
include the Cardiovascular Health Study (CHS), the 
FHS original and FHS offspring cohorts. We also 
compared LLFS participants to the New England 
Centenarian Study (NECS) [7] proband generation with 
the expectation that LLFS may show a similar or 
somewhat lower degree of exceptionality compared to 
this long lived cohort.  
 
METHODS 
 
Long Life Family Study. The Long Life Family Study is 
a family-based cohort study designed to determine both 
genetic and behavioral/environmental risk factors for 
familial exceptional survival traits, enrolling 4559 long-
lived probands and their siblings (n=1445), their 
offspring (n=2329) and spouse controls (n=785).   
Family members (n=119) with only telephone interview 
data and a blood sample were excluded from these 
analyses. Thus, 3655 LLFS individuals with familial 
longevity (probands, siblings and their children) were 
compared to the other cohorts and the 785 spouse 
controls.  Telephone follow-up is ongoing to ascertain 
changes in health, function and vital status. 
 
Recruitment.  The U.S. field centers used Center for 
Medicare and Medicaid Services lists of Medicare 
enrollees to mail a recruitment brochure. The initial file 
included people who were at least 79 years old on 
January 1, 2005; had no recorded date of death; were 
not in the end-stage renal disease or hospice programs; 
lived in zip codes “near” (within 3 hours driving 
distance) one of the 3 U.S. study centers (Boston 
University Medical Center in Boston MA, Columbia 
College of Physicians and Surgeons in New York City 
NY, and the University of Pittsburgh in Pittsburgh PA). 
A pilot mailing tested the yield of families recruited 
from mailing to individuals in their 80’s and higher age 
strata. Based on these yields, subsequent mailings 
targeted those age 89 and older. Study participants were 
also recruited from local communities using mailed 
brochures, posters, web-based media and newspaper 
advertisements as well as community-based presenta-
tions. Additional mailing lists were obtained through 
voter registries and purchased public domain lists from 
various commercial vendors.  
 
The University of Southern Denmark field center 
identified individuals who would be ages 90 and above 
during the study recruitment period through the Danish 
National Register of Persons, which contains current 
information on names, including past names such as 
maiden names for women, addresses, place of birth, 
marriages, and vital status [8]. Second, using 
information on the place of birth and the names, parish 
registers available in regional archives were searched to 
locate the parents of the elderly individuals in order to 
identify sibships. Based on the above information, 
potentially eligible families were identified and contact 
was made with potential probands to further assess the 
family’s eligibility for and willingness to participate in 
the LLFS using criteria parallel to that used in the 
United States. 
 
Eligibility and Enrollment.  All potential probands were 
pre-screened for eligibility by telephone.  Potential 
probands were asked questions about their family, 
including birth and/or death dates of all their brothers 
and sisters.  The Family Longevity Selection Score 
(FLoSS) [9] was calculated to rank sibships by current 
age or age at death of siblings, the size of the sibship 
and the number of alive individuals available for study. 
This ranking led to the enrollment of families with the 
greatest potential utility for phenotypic and genetic 
studies of exceptional survival in families.   
 
If a proband’s family was FLoSS eligible, defined as a 
score of 7 or higher, they also had to meet the following 
criteria: 1) the proband, at least one living sibling, and 
one of their living offspring (minimum family size of 3) 
were all able to give informed consent, and 2) were 
willing to participate in the interview and examination 
including the blood sample for serum and DNA 
extraction. The probands were asked to contact other 
potentially interested family members for enrollment. 
Prior to examination, written informed consent was 
obtained from all enrollees. In a few cases of cognitive 
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consent, provided that the participant was able to 
express assent at the time of the examination. 
 
 Examination.  The interviews and examinations were 
conducted in the home setting with portable equipment 
by centrally trained and certified research assistants 
using a common protocol. U.S. research technicians 
also traveled to examine families and family members 
outside of the field center regions (about 20% of the 
U.S. sample) when the family was highly exceptional 
(FLoSS >15) or to enroll additional family members 
who resided outside of the field center regions. If an in-
person visit was not feasible, a comprehensive 
telephone interview was conducted and a blood or 
saliva sample was obtained by an outside laboratory or 
physician’s office.   
 
Date of birth was validated using a driver’s license, 
birth certificate or other official document or source. 
Sex, race, ethnicity, and education were self-reported. 
History of disease was assessed by self-report of a 
physician diagnosis and approximate date of onset for 
the following:  heart disease (heart attack or myocardial 
infarction, and/or coronary artery bypass surgery), 
stroke (stroke and/or transient ischemia attack), 
hypertension, diabetes, chronic lung disease 
(emphysema, chronic bronchitis and/or asthma), 
peripheral artery disease and cancer.  
 
Standing height was measured using a Handi-stat set 
square (Perspective Enterprises, Portage, MI) to the 
nearest 0.1 cm.  Weight was measured using an 
electronic digital scale (SECA 841, Hanover, MD) to 
the nearest 0.1 kg. Body mass index (BMI) was 
calculated as weight (kg)/height (m)
2.   Sitting blood 
pressure was measured using an automated blood 
pressure machine (BP-tru BPM 300, VMS MedTech, 
Coquitlam, Canada), averaging three measures. Pulse 
pressure was calculated as systolic blood pressure 
(SBP) minus diastolic blood pressure (DBP).  Lung 
function was measured with a portable spirometer 
(EasyOne™, ndd Medical Technologies, Andover, MA) 
using American Thoracic Society guidelines. Ankle-arm 
index, the ratio of the ankle to arm systolic blood 
pressure, was used to assess peripheral arterial disease. 
Physical function was assessed with questions regarding 
difficulty with activities of daily living (ADL’s), 
instrumental activities of daily living (IADL’s) and 
mobility. Performance measures of function included 
gait speed, chair stands and standing balance [10].  Grip 
strength (average of two trials) was measured using an 
isometric dynamometer (Jamar Hydraulic Hand 
Dynamometer, Lafayette, IN) in a seated position to the 
nearest 2 kg. Cognitive testing included the Mini-
Mental State Exam (MMSE) [11] and the Digit Symbol 
Substitution Test (DSST) [12]. Total cholesterol, high 
density lipoprotein – cholesterol (HDL-C), low density 
lipoprotein – cholesterol (LDL-C), triglycerides, 
creatinine and blood glucose were assessed after at least 
a 6 hour fast and analyzed by the LLFS central 
laboratory based at the University of Minnesota.  
 
Reported hypertension and diabetes were confirmed by 
specific medication use based on a medication 
inventory of all prescription and over-the-counter 
medication taken in the past two weeks. Medications 
were coded into major categories, including anti-
hypertensives, anti-anginals, oral hypoglycemics and 
insulin, lipid lowering drugs and “other”. For analysis, 
hypertension was defined as SBP ≥ 140 mmHg or DBP 
≥ 90 mmHg or self-report confirmed by use of anti-
hypertensive medications.  Diabetes was defined as use 
of diabetes medications or fasting glucose ≥ 126 mg/dL. 
Three ADLs were assessed in LLFS comparably to 
other studies: bathing/showering, walking up 10 steps 
and getting in/out of a bed or chair.  ADL difficulty was 
defined as having difficulty with at least one of these 
three items. Detailed cognitive testing and personality 
[13] were assessed and are reported separately.  Other 
behavioral and environmental characteristics assessed 
included past and current physical activity levels [14] 
and smoking history, defined as current, past, or never.  
 
Comparison Cohorts. The Framingham Heart Study and 
the CHS included many of the same measures as were 
used in LLFS. The Cardiovascular Health Study is an 
ongoing prospective, observational study designed to 
determine the risk factors for, and consequences of, 
cardiovascular disease in older adults.  A total of 5,888 
participants across four U.S. field centers were recruited 
[15]. Data from the baseline examination, conducted in 
1989-1990 (and 1992-1993 for the 687 minorities) were 
used for the comparison. The Framingham Heart Study 
original cohort consisted of 5,209 respondents in 1948 
from a random sample of adult households in 
Framingham, Massachusetts, age 30 to 62 years. 
Because specific exam components were comparable 
with LLFS, data from exam 26 (1998-2001) were used 
for the comparison[16].The Framingham Heart Study 
offspring cohort was initiated in 1971[17].A sample of 
5,124 men and women, consisting of the offspring of 
the FHS original cohort, their spouses and random 
sample of the Framingham population was included. 
Data from the FHS offspring cohort exam [7] (1998-
2001) were used for this comparative analysis. The New 
England Centenarian Study began in 1994 as a 
population-based study of all centenarians living within 8 
towns in the Boston area [18]. The New England 
Centenarian Study has gone on to enroll subjects age 96 
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and offspring from throughout the United States.  
 
For each cohort, items were selected that were assessed 
in a comparable fashion to LLFS [15,18,19].  In the 
CHS and NECS, self-reported medical history items 
were similar to LLFS. For the Framingham cohorts, 
heart disease, stroke and cancer were adjudicated by 
review of records.  For heart disease, components of the 
diagnosis were not available to make it comparable with 
LLFS, and therefore, it was not used in this analysis.  
Hypertension and diabetes definitions were constructed 
to be similar across studies, combining self-report, 
measured blood pressure or blood glucose and 
medication use. Three self-reported disability items 
were comparable between LLFS and CHS, but differed 
for NECS and FHS. The protocols for the MMSE were 
the similar across studies [15,18,19] and DSST was 
similar between CHS and LLFS [15]. Performance 
measures of gait speed and grip strength were assessed 
in CHS and FHS with slightly different protocols, but 
all reported results in meters per second. In CHS, the 
course was 15 feet compared to 4 meters in both 
Framingham cohorts and LLFS. Grip strength was 
assessed with the forearm supported in CHS and FHS 
and not supported in LLFS, making it somewhat more 
challenging. Anthropometry protocols, smoking status, 
and medication use definitions were comparable. Blood 
was drawn in the fasting state, except in the FHS 
original cohort, where a random sample was obtained, 
thus fasting glucose was not available in that cohort. All 
assays were conducted using standard protocols for 
each study in a central lab [15,19]. 
 
Statistical Analysis. Descriptive means and proportions 
were assessed for LLFS overall as well as for each 
generation. For dichotomous outcomes, the LLFS 
cohort was stratified by generation, and adjusted 
pairwise comparisons were performed with the age 
range of each cohort restricted to match the age range of 
the LLFS generation to which it was compared.  For 
example, the oldest (proband) LLFS generation had 
members age 72 to 100 years.  In this generation’s 
comparison with CHS participants, the analysis group 
was limited to an age range of 72 to 100 years in CHS.  
Similarly, the analysis comparing the offspring LLFS 
generation to CHS was limited to participants aged 65 
to 88 years, with this range including members from 
both CHS and LLFS offspring generation cohorts.   
Thus, each comparison shows a different subset of 
LLFS. We were not able to match for birth cohort.  For 
continuous variables, similar generation-stratified 
analyses were performed using generalized linear 
models adjusted for age, race, sex, education level, and 
smoking status with means and frequencies centered at 
the LLFS cohort means for the generation in the 
analysis. Additionally, clustering of familial traits in 
LLFS and FHS was adjusted for by controlling for 
family membership using an exchangeable correlation 
structure.  Models examining creatinine were additionally 
adjusted for height and weight.  Blood pressure means 
were adjusted for anti-hypertensive medication use and 
lipid levels were adjusted for use of lipid lowering 
medications. Interactions for age and sex were tested in 
all models and none were statistically significant. SAS 
version 9.1 (Cary, NC) and the GEE package in R 
version 2.7 were used to perform the analyses. 
 
RESULTS 
 
The Long Life Family Study cohort had a wider range 
of ages than any of the other cohorts (Table 1).  The 
mean age in CHS was similar to LLFS, though limited 
to age 65 and over at the younger end of the 
distribution. The Framingham Heart Study original 
cohort was older than both LLFS and CHS, while the 
FHS offspring cohort was more similar in age to LLFS.  
The NECS had the oldest individuals, with a mean age 
of 102.8 years, ranging from 90 to 119 years, similar to 
the LLFS probands generation. The Long Life Family 
Study cohort was more highly educated compared to 
CHS, NECS and FHS and this was more apparent in the 
LLFS offspring generation.  History of smoking was 
similar among LLFS, CHS and FHS, with about 40-50% 
of participants with no history of smoking.  In the NECS, 
80% of participants reported that they never smoked. 
 
Table 2a presents the odds ratios for disease prevalence 
in the LLFS proband generation cohort compared to 
similarly aged subsets of the other comparison cohorts.  
The odds ratio for heart disease, stroke and 
hypertension was similar to or lower in the comparison 
cohorts compared to LLFS probands except for  the 
FHS original cohort which had had a significantly 
higher risk of hypertension compared to the LLFS 
cohort.  In the case of diabetes, FHS offspring cohort 
had higher prevalence compared to LLFS probands; 
there was no difference in diabetes between CHS or 
NECS participants. The prevalence of cancer was 
significantly lower for FHS offspring cohort compared 
to the LLFS cohort, with no differences found between 
the other cohorts and LLFS.  Self-reported history of 
lung disease was more than three times more prevalent 
in the CHS cohort, compared to the LLFS, p<0.0001.  
The risk of having peripheral artery disease (defined as 
an ankle-arm index <0.9) was three times more likely in 
the CHS compared with the LLFS participants.  Further, 
the risk of gait speeds of <1.0 m/s were nearly four 
times more likely for the CHS participants as compared 
to LLFS, p<0.0001. 
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Table 1.  Socio‐demographic, health and functional characteristics of LLFS and comparison cohorts 
 
   LLFS*  LLFS 
Probands* 
LLFS 
Offspring*  CHS  FHS–
Original 
FHS–
Offspring  NECS  LLFS 
Controls 
   N = 3690  N = 1373  N = 2317  N = 5888  N = 542  N = 3475  N=1088   N = 582 
Socio-Demographic                         
Age                         
Mean ± SD  72.5 ± 16.4  91.0 + 6.1  61.0 + 8.3  72.8 ± 5.6  86.2 ± 4.1  61.4 ± 9.6  102.8 ± 4.04  61.8 ± 8.6 
Range  31 - 110  72 - 110  31 - 88  65 - 100  79 - 103  33 - 90  90 - 119  25 - 88 
Gender (%)                         
Male  44.1 47.0 42.3 42.4  30.3 46.0 27.4  52.1 
Female  55.9 53.0 57.7 57.6  69.7 54.0 72.6  47.9 
Race (%)                         
White  99.3 98.9 99.6 83.6  100.
0  100.0 97.4  99.0 
Non-White  0.7 1.1 0.4  16.4  0.0 0.0 2.6  1.0 
Education (%)                         
Less than High School  13.8  26.4 6.0  29.5  25.4 5.8  60.6  11.0 
High School or 
equivalency  13.4 22.1  8.1 27.6  39.0 33.1 18.7  4.5 
More than High School  72.8  51.5 85.9 42.9  35.6 61.1 20.8  84.5 
Smoking Status (%)                         
Never Smoked  54.4  57.6  52.3 46.6  39.0 36.2 80.2  49.8 
Former Smoker  38.3  39.5  37.6 41.5  57.0 50.0 17.3  41.0 
Current Smoker  7.3  2.9  10.1 11.9 4.0 13.8  2.5  9.2 
Medication Use  (%)                         
Lipid-Lowering 
Medications  16 19 14  5  23 21      16 
Anti-Hypertensive 
Medications  43 67 28 31  62 34      28 
Disease Prevalence (%)                         
Heart Disease  9.2  17.7  3.9 11.9  N/A N/A 10.0  5.7 
Stroke  7.7  15.9 2.5 4.3  10 3.0  15.7  3.6 
Hypertension 52.2  66.3  43.4 54.5  82.6 37.1 37.6  46.6 
Diabetes  4.7 6.0 3.9 8.5  36.6  11.7 6.7  3.4 
Cancer  15.5 23.5 10.5 14.3  22.7  8.8 21.1  12.7 
Chronic Obstructive Lung 
Disease  6.7 8.2 5.7  23.8  N/A N/A  4.4  13.1 
Peripheral Artery Disease  7.0  17.9 0.9  13.4  N/A 2.6 9.3  1.7 
Activities of Daily Living, 
difficulty with one or 
more 
18.0 40.1  4.4 14.3  N/A N/A N/A  7.6 
                          
Physical Measures (Mean ± 
SD) 
                       
                          
Height (cm)  165.1 ± 10.7  160.1 + 10.3  168.0 + 9.7  164.8 ± 9.5  159.9 ± 9.2  167.5 ± 9.4     169.9 ± 9.2 
Weight (kg)  74.2 ± 17.2  66.9 + 14.0  78.5 + 17.5  72.7 ± 14.7  66.2 ± 13.5  79.1 ± 16.8     79.3 ± 16.0 
Body Mass Index (kg/m²)  27.1 ± 5.2  26.0 + 4.3  27.8 + 5.5  26.7 ± 4.7  23.3 ± 4.3  28.2 ± 5.3     27.4 
Gait Speed (m/s)  1.00 ± 0.32  0.72 + 0.26  1.17 + 0.22  0.86 ± 0.22  0.80 ± 0.22  N/A     1.2 
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Average Grip (kg)  27.4 ± 11.8  19.6 + 8.1  32.1 + 11.2  28.5 ± 10.5  18.7 ± 8.2  N/A     34.3 
Digit Symbol 
Substitution Test  42.5 ± 17.0  27.3 + 12.9  50.9 + 12.5  36.4 ± 13.5  N/A  N/A     47.6 
Mini-Mental State Exam  27.4 ± 3.7  25.1 + 4.4  28.9 + 2.2  27.8 ± 2.5  25.9 ± 5.3  N/A     28.6 
Systolic Blood Pressure 
(mmHg)  132.0 ± 22.6  138.3 + 
25.5  128.1 + 19.5  136.6 ± 21.8  141.4 ± 22.6  124.6 ± 18.9     131.3 ± 20.6 
Diastolic Blood Pressure 
(mmHg)  76.8 ± 11.6  73.3 + 12.0  79.0 + 10.8  70.7 ± 11.4  70.1 ± 11.8  73.4 ± 10.5     80.1 
Pulse Pressure  55.2 ± 18.8  65.0 + 20.8  49.1 + 14.4  65.8 ± 18.7  71.4 ± 19.4  51.2 ± 17.2     51.2 ± 14.9 
Fasting Glucose (mg/dL)  95.1 ± 20.4  96.2 + 22.1  94.4 + 19.1  111.2 ± 37.3  N/A  104.4 ± 27.4     98.4 ± 19.7 
Cholesterol (mg/dL)  198.7 ± 42.3  187.5 + 
43.5  205.6 + 40.1  211.2 ± 39.3  185.4 ± 36.2  200.3 ± 36.8     207.1 ± 41.0 
High-Density 
Lipoprotein Cholesterol 
(mg/dL) 
58.6 ± 17.4  55.9 + 16.0  60.3 + 18.0  54.2 ± 15.7  55.0 ± 17.5  53.7 ± 17.0     58.7 ± 16.7 
Low-Density Lipoprotein 
Cholesterol (mg/dL)  117.6 ± 35.5  109.4 + 
35.6  122.6 + 34.5  129.8 ± 35.7  101.0 ± 31.4  119.4 ± 33.2     125.9 ± 34.9 
Triglycerides (mg/dL)  113.4 + 70.8  110.4 + 
59.8  115.2 + 76.8  139.6 ± 76.9  146.8 ± 75.6  137.1 ± 89.0     116.7 ± 83.8 
Creatinine (mg/dL)  1.06 + 0.35  1.20 + 0.44  0.98 + 0.26  1.07 ± 0.4  1.24 ± 0.42  1.07 ± 0.32     0.99 ± 0.20 
Forced Vital Capacity (L)  3.07 + 1.04  2.26 + 0.77  3.49 + 0.91  2.96 ± 0.87  N/A  N/A     4.47 ± 14.9 
Ankle-Arm Index  1.16 + 0.18  1.07 + 0.21  1.21 + 0.13  1.06 ± 0.18  N/A  1.15 ± 0.12     1.21 ± 0.14 
            
* Values are provided for entire cohorts, subsequent comparisons restricted to match age ranges of probands and offspring. 
 
Table 2a.  LLFS Probands: Odds ratios for disease and disability prevalence in comparison cohorts relative to LLFS; adjusted 
for age, sex, race, education and smoking status. 
 
  LLFS  CHS (N=2967)  FHS –Original 
(N=519) 
FHS-Offspring (N=541)  NECS-Proband (N=1088) 
  OR  OR  (95% CI)  OR  (95% CI)  OR  (95%CI)  OR  (95%CI) 
Heart Disease  1.00  0.68  (0.51-0.91)** N/A  N/A  0.89  (0.57-1.41) 
Stroke 1.00  0.52  (0.35-0.76)***  0.69  (0.47-0.99)* 1.02  (0.72-1.45)  0.88  (0.55-1.34) 
Hypertension 1.00  0.96  (0.76-1.20)  1.84  (1.36-2.49)*** 0.57  (0.50-0.65)**  0.48  (0.34-0.67)*** 
Diabetes 1.00  0.82  (0.56-1.22)  N/A  2.89 (2.17-3.84)**  1.93  (0.97-3.84) 
Cancer 1.00  0.79  (0.61-1.03)  1.02  (0.77-1.34) 0.71  (0.58-0.87)**  1.00  (0.68-1.47) 
Chronic Obstructive Lung 
Disease 
1.00 3.40  (2.53-4.56)***  N/A N/A  0.56  (0.30-1.07) 
Peripheral Artery Disease  1.00  3.00  (2.15-4.19)*** N/A  1.70  (0.95-3.05)  N/A 
Activities of Daily Living, 
difficulty with one or more 
1.00 1.28  (0.97-1.69) N/A  N/A  N/A 
Gait Speed, <1.0 m/s  1.00  3.99  (2.95-5.40)*** 1.14  (0.80-1.63)  N/A  N/A 
LLFS N’s:  CHS vs. LLFS N = 1382; FHS‐Original vs. LLFS N = 1366; FHS‐Offspring N = 573; NECS‐Proband vs. LLFS N = 954 
*  p ≤ 0.05 
**  p ≤ 0.01 
***  p ≤ 0.001 
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Table 2b presents the odds ratios for disease prevalence 
in the LLFS offspring generation cohort and in the 
similarly aged subsets of CHS, FHS original, FHS 
offspring, and LLFS spousal controls. Heart disease 
prevalence among CHS participants was more than two 
times higher compared to the LLFS offspring.  There 
were no differences in self-reported history of stroke 
among the CHS, FHS original, FHS offspring and the 
LLFS cohort.  However, the odds of stroke were more 
than two-fold higher for LLFS spouse controls 
compared to LLFS offspring.  CHS and FHS original 
cohorts had significantly lower risk of hypertension 
compared to the LLFS offspring.  For diabetes, CHS 
and FHS offspring cohorts had higher prevalence 
compared to LLFS offspring.  The prevalence of cancer 
was significantly lower by 20% for the FHS offspring 
cohort compared to the LLFS cohort, with no 
differences found between the other cohorts and LLFS 
offspring. The CHS cohort had a nearly 2.5-fold  greater  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
prevalence of self-reported history of lung disease 
compared to the LLFS. Peripheral artery disease risk 
was three times more likely in the CHS compared with 
the LLFS offspring cohort. In addition, the risk of gait 
speeds of ≤1.0 m/s were nearly five times more likely 
for the CHS participants as compared to LLFS 
offspring, p<0.0001. 
 
Adjusted mean differences in blood chemistries and 
physical characteristics were compared for LLFS, 
CHS, and FHS cohorts (Table 3a and 3b). LLFS 
proband generation participants had higher BMI 
compared to all other cohorts, but this was only 
statistically significant compared to the CHS cohort. 
For the LLFS offspring generation, BMI was higher 
compared to both the CHS and FHS original cohorts. 
Mean grip strength was higher for LLFS probands 
compared to FHS original cohort however, it was 
lower compared to CHS.  There were no statistically 
Table 2b.  LLFS Offspring: Odds ratios for disease and disability prevalence in comparison cohorts relative to LLFS, adjusted for 
age, sex, race, education and smoking status. 
 
  LLFS  CHS (N=5798)  FHS-Original (N=367)  FHS-Offspring 
(N=2946) 
LLFS Controls 
(N=777) 
  OR  OR  (95% CI)  OR  (95% CI)  OR  (95%CI)  OR  (95%CI) 
Heart Disease  1.00  2.12  (1.72-2.63)*** N/A  N/A  0.93  (0.42-2.08) 
Stroke 1.00  0.81  (0.63-1.04)  0.69  (0.46-1.03) 1.04  (0.73-1.49) 2.31  (1.18-4.51)* 
Hypertension 1.00  0.86  (0.74-0.99)*  1.97  (1.44-2.68)*** 0.74  (0.64-0.85)*** 1.12  (0.89-1.40) 
Diabetes 1.00  1.45  (1.06-2.01)*  N/A  5.41 (3.77-7.77)***  0.89  (0.42-1.87) 
Cancer 1.00  0.97  (0.80-1.18)  0.99  (0.76-1.32) 0.79  (0.64-0.98)*  0.97  (0.63-1.50) 
Chronic Obstructive Lung Disease  1.00  2.44 (1.99-2.99)***  N/A  N/A  1.19  (0.76-1.88) 
Peripheral Artery Disease  1.00  2.97  (2.19-4.03)*** N/A  1.39  (0.85-2.26)  2.93  (0.95-9.02) 
Activities of Daily Living, 
difficulty with one or more 
1.00 1.03  (0.84-1.26)  N/A N/A  1.09  (0.66-1.81) 
Gait Speed, <1.0 m/s  1.00  4.76  (3.92-5.80)*** 1.32  (0.91-1.92)  N/A  0.77 (0.57-1.06) 
LLFS N’s:  CHS vs. LLFS N =771; FHS‐Original vs. LLFS N = 50; FHS‐Offspring N = 2312; LLFS Controls vs. LLFS N = 2732 
*  p ≤ 0.05 
**  p ≤ 0.01 
***  p ≤ 0.001 
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LLFS offspring cohort and any of the comparison 
groups.  Long Life Family Study participants in both 
the proband and offspring generation had significantly 
faster walk speeds compared to CHS.   Similarly,  digit  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
symbol substitution test scores were significantly 
better for both LLFS cohorts compared to CHS.   
Additionally, there was a slight difference between the 
LLFS proband generation and FHS offspring cohort 
for the MMSE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3a.  LLFS Probands: Measurement means in LLFS and comparison cohorts r adjusted for age, sex, race, education and 
smoking status. 
 
  Cardiovascular Health Study  Framingham Heart Study - Original 
Cohort 
Framingham Heart Study - Offspring Cohort 
  ALL (72 - 100)  ALL (79 - 103)  ALL (72 - 90) 
 LLFS 
(N = 1386) 
CHS 
(N = 2964) 
 LLFS 
(N = 1369) 
FHS - 
Original 
(N = 322) 
 LLFS 
(N = 575) 
FHS - 
Offspring 
(N = 512) 
 
  Mean ± SE  Mean ± SE  Difference  Mean ± SE  Mean ± SE  Difference  Mean ± SE  Mean ± SE  Difference 
Anthropometrics 
Height (cm)  160.3±0.24  160.8±0.31 0.5  160.0±0.23  159.7±0.43 -0.3 162.6±0.34  162.6±0.61  0.0 
Weight (kg)  67.1±0.38  62.0±0.57  -5.1 ***  66.6±0.38 64.7±0.63  -1.9  *  71.3±0.59  69.0±1.06  -2.3 
Body Mass 
Index (kg/m²) 
26.0±0.14 23.9±0.20 -2.1  *** 25.5±0.14 25.4±0.28 -0.2  26.9±0.21  26.1±0.39  -0.8 
Physical Function 
Gait Speed 
(m/s) 
0.72±0.01 0.62±0.01 -0.1  *** 0.71±0.01 0.72±0.01  0.0       
Average Grip 
Strength 
(kg) 
19.8±0.20 21.1±0.34  1.3  **  19.4±0.19 18.3±0.32 -1.1  **       
Cognitive Function 
Digit Symbol 
Substitution 
Test 
27.0±0.37  22.0±0.58  -5.0  ***           
Mini-Mental 
State Exam 
25.4±0.11 24.9±0.16 -0.5  **  25.2±0.12 24.4±0.29  -0.8 **  26.9±0.13  25.9±0.35  -1.0 ** 
Blood Pressure 
Systolic Blood 
Pressure
a 
(mmHg) 
138.3±0.74 144.7±1.10  6.4  *** 138.6±0.75  140.0±1.50  1.4  138.2±0.99 141.5±1.94  3.3 
Diastolic 
Blood 
Pressure
a 
(mmHg) 
73.3±0.36 66.9±0.56 -6.4  *** 73.2±0.36 69.3±0.77  -3.9 ***  73.9±0.48  66.7±0.97  -7.2 *** 
Pulse Pressure
a  65.0±0.61  77.7± 0.91  12.6 ***  65.4±0.61 70.8±1.28 5.4  ***  64.3±0.79 74.7±1.66  10.4  *** 
Fasting Glucose 
(mg/dL)
b 
96.1±0.65 109.0±1.17  12.9  ***       95.7±0.97  105.7±1.61  10.0  *** 
Lipids 
Cholesterol     
(mg/dL)
c 
187.4±1.34  199.4± 1.94  12.1 ***  187.1±1.32  181.4±2.49 -5.7  *  189.2±1.88 189.1±3.14  -0.1 
Low-Density   
Lipoprotein 
Cholesterol 
(mg/dL) 
109.2±1.09  121.1± 1.77  11.9 ***  109.2±1.10  100.4±2.15 -8.8  ***  109.5±1.56  111.0±2.77  1.5 
Kidney Function  109.6±1.79  129.5± 2.93  19.9 ***  110.2±1.80  139.3±4.49 29.1  ***  113.9±2.72 143.0±5.83 29.2  *** 
Lung Function 1.20±0.01  1.26±0.02  0.1  **  1.21±0.01 1.33±0.03  0.12  *** 1.16±0.02 1.26±0.03 0.10  ** 
Peripheral 
Arterial Disease 
2.24±0.02  2.33±0.03  0.1  *           
Ankle-Arm 
Index 
1.06±0.01 0.95±0.01  -0.12  ***       1.13±0.01  1.08±0.02  -0.05  ** 
*  p ≤ 0.05 
**  p ≤ 0.01 
***  p ≤ 0.001 
a  Model additionally adjusted for anti‐hypertensive medication use.
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Table 3b.  LLFS Offspring: Measurement means in LLFS and comparison cohorts adjusted for age, sex, race, education and 
smoking status. 
 
  Cardiovascular Health Study  Framingham Heart Study - Original 
Cohort 
Framingham Heart Study 
- Offspring Cohort 
LONG LIFE Family Study - Controls 
  ALL (65 - 88)  ALL (79 - 88)  ALL (33 - 88)  ALL (31 - 88) 
 LLFS 
(N =776) 
CHS 
(N=5804) 
LLFS 
(N=51) 
FHS - Original 
(N = 260) 
LLFS 
(N=2321) 
FHS – Offspring 
(N = 3247) 
LLFS 
(N = 
2744) 
LLFS Controls 
(N = 783) 
 Mean  ± 
SE 
Mean ± 
SE 
Difference Mean  ± 
SE 
Mean ± 
SE 
Difference Mean  ± 
SE 
Mean ± 
SE 
Difference Mean  ± 
SE 
Mean ±  
SE 
Difference 
Anthropometrics 
Height (cm)  166.5 
±0.30 
166.0 
±0.11  -0.4  162.1 
±1.01 
162.2 
±0.62  0.0  167.2 
±0.22 
166.3 
±0.14  -0.8 ***  167.3 
±0.21 
167.7 
±0.24  0.5 
Weight (kg)  77.5 
±0.58 
73.0 
 ±0.23  -4.5 ***  77.2 
±2.25 
70.5 
±1.16  -6.7 **  77.6 
±0.42 
77.1 
±0.32  -0.5  77.6 
±0.39 
77.4 
 ±0.52  -0.2 
Body Mass 
Index (kg/m²) 
27.9 
±0.21 
26.4 
 ±0.08  -1.5 ***  29.3 
±0.82 
26.3 
±0.43  -3.0 ***  27.7 
±0.15 
27.8 
±0.12  0.1  27.7 
±0.14 
27.4 
 ±0.18  -0.3 
Physical Function 
Gait Speed 
(m/s) 
1.11 
±0.01 
0.92 
±0.00  -0.2 ***  0.92 
±0.03 
0.90 
±0.02  0.0       1.12 
±0.01 
1.16 
±0.01  0.0 *** 
Average Grip 
Strength 
(kg) 
29.2 
±0.28 
29.7 
 ±0.13  0.5  22.8 
±1.04 
21.4 
±0.56  -1.3       30.7 
±0.19 
31.2 
 ±0.28  0.5 
Cognitive Function 
Digit Symbol 
Substitution 
Test 
44.4 
±0.52 
42.5 
 ±0.19  -1.9 ***              48.3 
±0.34 
47.4 
 ±0.45  -0.9 * 
Mini-Mental 
StateExam 
28.6 
±0.10 
28.5 
 ±0.03  -0.1  27.6 
±0.69 
27.8 
±0.26  0.2  28.7 
±0.06 
28.5 
±0.05  -0.2 **  28.7 
±0.05 
28.7 
 ±0.08  0.1 
Blood Pressure 
Systolic 
Blood 
Pressure
a 
(mmHg) 
134.1 
±0.84 
133.5 
±0.37  -0.6  140.3 
±2.82 
141.8 
±2.21  1.5  131.1 
±0.53 
126.8 
±0.42  -4.3 ***  129.5 
±0.46 
130.8 
±0.77  1.3 
Diastolic 
Blood 
Pressure
a 
(mmHg) 
77.9 
±0.42 
70.5 
 ±0.20  -7.4 ***  74.0 
±1.13 
71.3 
±1.11  -2.8  78.2 
±0.29 
72.2 
±0.24  -5.9 ***  78.3 
±0.26 
78.5 
 ±0.41  0.3 
Pulse 
Pressure
a 
56.1 
±0.65 
62.9 
 ±0.31  6.8 ***  66.2 
±2.39 
70.6 
±1.86  4.4  53.0 
±0.37 
54.6 
±0.36  1.6 ***  51.3 
±0.33 
52.3 
 ±0.51  1.1 
Fasting Glucose 
(mg/dL)
b 
79.8 
±0.79 
108.2 
±0.45  28.3 ***        95.4 
±0.48 
103.5 
±0.46  8.1 ***  94.6 
±0.46 
97.2 
 ±0.80  2.6 *** 
Lipids 
Cholesterol 
(mg/dL)
c 
203.5 
±1.87 
212.4 
±0.76  8.9 ***  196.2 
±6.28 
183.3 
±3.45  -12.9  205.8 
±1.17 
202.6 
±0.84  -3.2 *  203.2 
±1.04 
205.6 
±1.69  2.4 
High-Density 
Lipoprotein 
Cholesterol 
(mg/dL) 
61.1 
±0.77 
53.9 
 ±0.29  -7.2 ***  61.1 
±2.33 
55.0 
±1.53  -6.0 *  60.6 
±0.53 
55.4 
±0.37  -5.2 ***  59.9 
±0.48 
60.1 
 ±0.61  0.2 
Low-Density 
Lipoprotein 
Cholesterol 
(mg/dL) 
119.5 
±1.65 
130.2 
±0.73  10.7 ***  112.6 
±5.78 
100.9 
±3.00  -11.7  122.5 
±1.02 
120.8 
±0.77  -1.7  120.6 
±0.91 
123.7 
±1.51  3.1 * 
Triglycerides 
(mg/dL)c 
115.8 
±2.94 
146.2 
±1.56  30.4 ***  112.9 
±8.20 
137.0 
±6.74  24.1 *  115.2 
±2.09 
132.3 
±1.84  17.1 ***  114.6 
±1.79 
111.8 
±2.64  -2.8 
Kidney Function 
Creatinine 
(mg/dL)d 
1.01 
±0.01 
1.03 
±0.01  0.0 *  1.10 
±0.04 
1.14 
±0.04  0.04  1.00 
±0.01 
1.09 
±0.01  0.09 ***  1.00 
±0.01 
0.99 
±0.01  0.0 
Lung Function 
Forced Vital 
Capacity (L) 
3.13 
±0.03 
3.14 
±0.01  0.0             3.35 
±0.02 
3.37 
±0.03  0.0 
Peripheral Arterial Disease 
Ankle-Arm 
Index 
1.18 
±0.01 
1.10 
±0.00  -0.08 ***        1.24 
±0.00 
1.19 
±0.00  -0.05 ***  1.19 
±0.00 
1.19 
±0.01  0.0 
*  p ≤ 0.05 
**  p ≤ 0.01 
***  p ≤ 0.001 
a  Model additionally adjusted for anti‐hypertensive medication use. 
b  Model additionally adjusted for oral hypoglycemic or insulin use. 
c   Model additionally adjusted for lipid‐lowering medication use. 
d  Model additionally adjusted for height and weight. 
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had significantly higher DBP and lower pulse pressures 
compared to CHS (Tables 3a and 3b).  Pulse pressure 
was also significantly lower for LLFS proband 
generation compared with both FHS cohorts.  Also, 
ankle-arm index was significantly better for both LLFS 
cohorts compared to those in the CHS and the FHS 
offspring cohort.   
 
All lipid values were significantly better for LLFS 
proband and offspring generation compared to CHS, 
including lower total cholesterol, lower LDL-C and 
lower triglycerides.  Triglycerides were lower for Long 
Life Family Study probands and offspring compared to 
both FHS cohorts.  Both LLFS cohorts consistently 
exhibited higher levels of HDL-C, by about 5 mg/dL 
(Tables 3 and 3b) compared to CHS.  Glucose levels 
were  significantly  lower by  about 13 mg/dL for  LLFS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
probands and 28 mg/dL for LLFS offspring compared 
to CHS.  Kidney function was better for LLFS proband 
and offspring generations when compared to CHS, FHS 
original and FHS offspring as exhibited by lower 
creatinine levels.   
  
For each measure, interactions with age were tested to 
determine if the differences between LLFS and the 
other cohorts might be greater at either extreme of age. 
There were no significant interactions however, age-
specific analyses suggested several interesting patterns 
of age-related change. For pulse pressure, the 
differences between LLFS and other cohorts were most 
apparent after age 65. (Figure 1) Gait speed was higher 
in LLFS than the other cohorts (Figure 2). Digit symbol 
substitution test showed that LLFS participants had 
higher scores at every age, but with a similar age-
specific decline (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Pulse Pressure by age, adjusted for sex and anti‐hypertensive medication use 
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Figure 2.  Gait Speed (m/s) by age, adjusted for sex
 
Figure 3.  Digit Symbol Substitution Test (DSST) score by age
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Probands and offspring of the LLFS cohort were less 
likely to have diabetes, chronic pulmonary disease and 
peripheral artery disease than the CHS and FHS cohort 
members. Measures of physical function and 
cardiovascular risk factors were more optimal in LLFS 
compared to the other groups. High density lipids were 
higher and triglycerides were lower in LLFS probands 
and offspring. This is consistent with previous reports 
of the children of centenarians having better lipid 
profiles than controls [20]. These findings suggest that 
the strategy of recruiting families with a history of 
longevity yielded rates of healthy aging not unlike that 
seen when recruiting offspring of centenarians [21]. 
 
We were also able to compare the oldest LLFS 
participants to participants in the NEC Study.  These 
two groups appeared to be similarly exceptional in 
terms of history of major chronic disease although we 
did note a somewhat lower prevalence of cancer in the 
oldest members of LLFS. This is potentially due to the 
requirement in LLFS of an in-person examination, 
which excluded individuals with cancer under active 
treatment.  
 
Comparisons between the offspring and their spouse 
controls showed trends consistent with better health in 
the LLFS offspring, but were not as strong as for some 
of the cross-cohort comparisons. These analyses were 
limited by the smaller sample size of this control group, 
but do suggest caution in attributing all differences to 
genetic factors in that part of the differences might be 
attributable to the shared environmental component of 
familial relationships. 
  
One of the most consistent differences noted was a 
lower pulse pressure in the LLFS probands and 
offspring. The LLFS offspring had levels similar to 
individuals who were 5-10 years younger. This 
difference was due in part to a higher DBP in LLFS, as 
well as a lower systolic pressure. A low DBP with aging 
is associated with vascular stiffness as diastolic pressure 
tends to go down as SBP increases with age [22]. Thus, 
a widening pulse pressure has been viewed as a sign of 
accelerated vascular aging and will be an important 
phenotype for future genetic analysis of exceptional 
survival. Less widening of pulse pressure with age 
would be consistent with, consistent with a slower “rate 
of aging” phenotype.  
 
Other age-specific differences suggested interesting 
patterns of age associated differences. The gait speed 
appeared to have a threshold of decline in LLFS with a 
much steeper decline after age 70, consistent with the 
idea that aging phenotypes can be manifest as a later 
onset of decline. Cognitive function as assessed by the 
DSST was higher at all ages in LLFS compared to CHS, 
consistent with the idea that they might have achieved a 
higher level of peak cognitive function earlier in life. 
This was not explained by their higher level of 
education. Conceptually, these patterns point to the 
need to consider “peak (or reserve) capacity [23], the 
“age of onset” of aging changes and the “rate of aging” 
as potentially distinct aspects of aging phenotypes that 
may vary across systems within an individual and 
require longitudinal data to establish.  Longitudinal data 
in LLFS will be important to distinguish between these 
pathways to becoming successfully aged. 
 
In spite of a lack of consistent difference in heart 
disease prevalence, the lower pulse pressure and other 
cardiovascular risk factors suggest that LLFS 
participants are healthier in terms of cardiovascular risk.  
Cardiovascular disease has a major environmental 
component in that there are several modifiable 
behavioral risk factors including diet, smoking and 
physical activity, and familial correlation of these 
factors could explain part of the associations seen. 
However, cardiovascular disease also has a significant 
genetic component. More detailed phenotyping with a 
continuous measure of atherosclerotic disease may 
improve our ability to detect familial associations and to 
sort out genetic vs. environmental components. 
 
For the purpose of determining genetic contributions to 
longevity, “disability-free survival” as a phenotype may 
capture the joint effects of multiple chronic diseases of 
aging and the subject’s ability to effectively deal with 
those diseases in order to maximize functional 
independence. Long Life Family Study participants had 
better physical functioning, based on assessments of 
gait speed and reported ADL difficulty. Physical 
functioning can be viewed as a summary measure of the 
impact of multiple conditions on health [24]. Gait speed 
differed between LLFS and other cohorts more than 
grip strength. This was unexpected given the robust 
ability of grip strength to predict mortality from middle 
age [24]. The grip strength protocol used in LLFS was 
slightly more difficult than used in the other cohorts and 
this may have obscured true differences. The Mini-
Mental State Exam did not differ among these groups, 
but the measure used was designed to detect dementia 
and would be insensitive to detecting cognitive function 
differences within the normal range. More detailed 
analysis on a full battery of higher order cognitive 
function domains might reveal specific differences.  
 
Functional status in older adults has been associated 
with various measures including muscle mass and 
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30]. Subclinical disease, especially cardiovascular 
disease, can be a strong determinant of function [31] as 
well as survival [32]. A challenge in the study of 
disability-free survival amongst aging adults 
predisposed to exceptional longevity is that its 
expression can occur late in very old age. In other 
words, disability per se is often not expressed until very 
late in life [33, 34]. Potentially, the continuous 
measures of function and the underlying physiology 
(e.g. gait speed, muscle strength, pulmonary function) 
may be more sensitive in detecting aspects of “rate of 
aging”, “age of onset” or “reserve capacity” and the 
predecessors of disability, which in turn could be 
valuable phenotypes for association and linkage studies 
of exceptional survival endophenotypes.   
 
The Long Life Family Study is a novel cohort study. 
Future analysis will be strengthened by increasing the 
depth of the phenotypic characterization including 
longitudinal assessments. Several limitations of this 
analysis include the known protocol differences 
between studies and the potential that there are birth 
cohort differences that could not be examined. The 
differences found were independent of major behavioral 
risk factors such as smoking and education, but a major 
challenge to these assessments is the difficulty in fully 
capturing lifetime environmental risk factors, thus 
adjustment may not have been complete. 
 
In summary, by selecting families characterized by 
having a strong history of longevity, we have identified 
individuals who have lower cardiovascular risk factors 
and higher levels of physical function. These findings 
suggest several priority phenotypes for inclusion in 
future genetic analysis to identify the loci contributing 
to exceptional survival. 
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